Tanezumab

Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia[1][2].

Product Specifications

CAS Number

[880266-57-9]

Product Name Alternative

RN-624; PF 4383119

UNSPSC

12352203

Target

Trk Receptor

Type

Inhibitory Antibodies

Related Pathways

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tanezumab.html

Purity

99.52

Solubility

10 mM in DMSO

Smiles

[Tanezumab]

Molecular Weight

(145.44 kDa)

References & Citations

[1]Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53. |[2]Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. The Journal of Pain, 2009, 10 (4) : S44. |[3]Peng T, et al., Nerve Growth Factor (NGF) Encourages the Neuroinvasive Potential of Pancreatic Cancer Cells by Activating the Warburg Effect and Promoting Tumor Derived Exosomal miRNA-21 Expression. Oxid Med Cell Longev. 2022 Oct 15;2022:8445093.|[4]Haifan W, et al. Nerve growth factor monoclonal antibody Tanezumab alleviates Kashin-Beck Disease Rat pain by impacting DRG signal transduction[J]. 2023.